Asthma

A meta-analysis shows an association between respiratory burden and greater dementia risk, but the causes are still unknown.

A long-term comparison trial with smokers motivated to quit show the combination of alternative nicotine products could slightly and safely improve cessation.

A comparison of virtual training to in-person education showed the former was noninferior to the latter among patients with asthma or COPD.

An international, 5000-patient cohort shows a majority of patients are white, female, and non-smokers.

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

How to weigh the 5 agents from the drug class, which have each shown differing benefit in younger patients.

For what other indications, and in what regimens, are investigators assessing the drug class?

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

How the greatest use of the drug class may just come in the most severe cases.

The rate of pediatric and adolescent patients adhering to 30-day corticosteroid refill schedules increased by nearly 50 percentage points.

The ALK-Abello expert details the positive findings from the vast, novel assessment of Ragwitek in children with ragweed allergic rhinitis with or without conjunctivitis.

New findings show Viaskin Peanut provided significant improvements to HRQL over placebo in a pair of its clinical trials.

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

Clinicians now have 5 agents to select from—but a limited variation of action, and an even more concise patient population eligible for treatment.

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

A new survey shows patients and family members prefer telemedicine physician visits as much as they do in-person appointments—or even more so than the latter.

A new assessment shows patients younger and older than 40 years both benefit in exacerbation rate and pre-bronchodilator FEV1.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

Asthma burden among women can vary based on their age. Are there varying methods of care?

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.

The drug class has become a mainstay in clinical practice and treatment plans. But could it reach greater, and wider, indications?

Investigators found similar rescue treatment use among patients who do and do not have frequent exacerbations.

A study observing the effect of formulary changes to children with asthma show FEV and FEF scores worsened significantly when switching inhaler types.